Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Shareholders have approved the proposed arrangement with Hanmi, which enables continued and expanded development of the TUS+VEN+AZA triplet

  60% confidence

• The clinical trial data continue to support the promise of TUS+VEN+AZA therapy

  60% confidence

• TUS+VEN+AZA triplet has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML

  60% confidence

• TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations

  60% confidence

Cited in these Via News reports

• AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
• Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
• Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →